This is only huge. FDA rarely allows results of post-facto analysis onto drug labels. Detailers can now point to the diverging curves and suggest earlier use of Jakafi in minimally-sick MF patients.
Consider the difference: before, salespeople were only allowed to tell physicians that if they contacted the company they could get more references to clinical data. If FDA had allowed references onto the label, the salespeople could have carried reprints with them, but they'd have been on shaky ground discussing the findings. With the curves on the label, they can basically tell the whole story.
And certain annoying people who keep saying "It only relieves symptoms" can choke on their own bile.